319 results
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
9 May 24
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
7:00am
may be contingent upon verification and description of clinical benefit in confirmatory trials.
U.S. IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS … or end-stage renal disease requiring dialysis.
The safety and effectiveness of Galafold have not been established in pediatric patients.
To report
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
9 May 24
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
7:00am
and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able … , including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/Galafold.pdf. For further important safety information for Galafold
8-K
EX-99.1
meumjsox2hyirtvh16t
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
8-K
EX-99.2
wssonm9oyi5wx4iuzuzg
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
8-K
EX-99.1
xtnavw 6qb
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
8-K
EX-99.2
seqk5rxqjo s7a9u
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
8-K
EX-99.1
6k4o80mkxu
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.2
t91fsy858pxnpqrytb
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-10.2
6f3ar7 iivussupibs3
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-10.1
q8ys52efte2toh9iqw3
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.1
mcs0t4w
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm
8-K
EX-99.1
7jhigv8soy 1tl
27 Sep 23
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
7:00am
8-K
EX-99.1
e8m15n6d79wfpmnk
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am